Literature DB >> 29061241

Central Nervous System Manifestations of Antiphospholipid Syndrome.

Jonathan Graf1.   

Abstract

Neurologic manifestations are common in patients with antiphospholipid antibodies and include stroke, seizures, dementia, cognitive dysfunction, chorea, migraine, psychosis, and demyelinating disease. Many of these disorders mimic their idiopathic counterparts, yet treatment for antiphospholipid antibody-associated disease can be quite different compared with treatment of CNS disease not associated with these antibodies. For patients with antiphospholipid antibody-associated neurologic disease, anticoagulation or immunosuppressive therapy or both may significantly improve their symptoms. Thus, one should have a high index of suspicion for antiphospholipid syndrome in the appropriate clinical context.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiphospholipid syndrome (APS); Central nervous system (CNS); Chorea; Cognitive disorder; Psychosis; Seizure; Sinus thrombosis; Stroke

Mesh:

Year:  2017        PMID: 29061241     DOI: 10.1016/j.rdc.2017.06.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  7 in total

1.  Multiple embolic strokes in primary antiphospholipid syndrome.

Authors:  Jesus A Garcia-Diaz; Ricardo Alvarez-Santana; Mara Escudero-Salamanca; Eulo Lupi-Herrera; Nilda Espinola-Zavaleta
Journal:  Eur J Rheumatol       Date:  2020-07-21

Review 2.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

3.  Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Authors:  Dolores Pérez; Ljudmila Stojanovich; Laura Naranjo; Natasa Stanisavljevic; Gordana Bogdanovic; Manuel Serrano; Antonio Serrano
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

4.  The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.

Authors:  Gilberto Pires da Rosa; Bernardo Sousa-Pinto; Ester Ferreira; Olga Araújo; Giuseppe Barilaro; Paulo Bettencourt; Ricard Cervera; Gerard Espinosa
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

Review 5.  Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence.

Authors:  Alfonso-Ragnar Torres-Jimenez; Virginia Ramirez-Nova; Adriana Ivonne Cespedes-Cruz; Berenice Sanchez-Jara; Alejandra Velazquez-Cruz; Vilma Carolina Bekker-Méndez; Francisco Xavier Guerra-Castillo
Journal:  Pediatr Rheumatol Online J       Date:  2022-02-14       Impact factor: 3.054

6.  A retrospective review of antiphospholipid syndrome from a South Asian country.

Authors:  Muhammad Zain Mushtaq; Syed Ahsan Ali; Zaibunnisa Sattar; Saad Bin Zafar Mahmood; Tazein Amber; Mehmood Riaz
Journal:  Arch Rheumatol       Date:  2021-10-18       Impact factor: 1.007

7.  Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.

Authors:  Laura Naranjo; Ljudmila Stojanovich; Aleksandra Djokovic; Laura Andreoli; Angela Tincani; Maria Maślińska; Savino Sciascia; Maria Infantino; Sara Garcinuño; Kinga Kostyra-Grabczak; Mariangela Manfredi; Francesca Regola; Natasa Stanisavljevic; Milomir Milanovic; Jovica Saponjski; Dario Roccatello; Irene Cecchi; Massimo Radin; Maurizio Benucci; Daniel Pleguezuelo; Manuel Serrano; Yehuda Shoenfeld; Antonio Serrano
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.